Navigation and service

You are here:Rote-Hand-Briefe and Information Letters

Information Letter on flupirtine: Recall and revocation of marketing authorisation

Date 2018.06.04
Active substance flupirtine

Following the European benefit-risk assessment, marketing authorisations of medicinal products containing the active substance flupirtine are revoked on an EU-wide level due to the risk of liver damage.